Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Dihexa vs Adamax

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Dihexa and Adamax share the nootropic class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer Adamax has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Adamax's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Dihexa

Preclinical + Anecdotal

Adamax

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: very limited human data. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Dihexa Adamax
Class Angiotensin IV analog; HGF potentiator Modified Semax analog (nootropic)
Drug class Cognitive Cognitive
Mechanism Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation Similar to Semax; BDNF/NGF upregulation; enhanced stability
Route Oral / Transdermal Intranasal
Half-life ~10 hrs ~minutes
Dosage (research) 8-45 mg oral daily (anecdotal) 200-600 mcg intranasal daily
Evidence tier Preclinical + Anecdotal Anecdotal
Research depth 17 indexed (PubMed 11 · CT 0 · EPMC 6) 6 indexed (PubMed 6 · CT 0 · EPMC 0)
Availability Research Chemical Research Chemical
Reported risks Very limited human data; theoretical tumor risk via HGF pathway Very limited human data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Dihexa or Adamax?

Dihexa and Adamax share the nootropic class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer Adamax has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Adamax's evidence base is currently denser.

What is the difference between Dihexa and Adamax?

Dihexa is classed as Angiotensin IV analog; HGF potentiator; Adamax is classed as Modified Semax analog (nootropic). Reported mechanism: Dihexa, Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation; Adamax, Similar to Semax; BDNF/NGF upregulation; enhanced stability. Reported half-life: Dihexa, ~10 hrs; Adamax, ~minutes. Routes in published studies: Dihexa, Oral / Transdermal; Adamax, Intranasal.

Which has stronger evidence, Dihexa or Adamax?

Adamax has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dihexa is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 17 indexed studies. Adamax is graded Anecdotal, with 6 cited sources on its reference page and 6 indexed studies.

Which is more accessible, Dihexa or Adamax?

Neither Dihexa nor Adamax is an FDA-approved drug. Catalog status: Dihexa, Research Chemical; Adamax, Research Chemical. Dihexa's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are Dihexa and Adamax ever combined?

Dihexa and Adamax appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…